China SXT Pharmaceuticals（SXTC）株式概要製薬会社であるChina SXT Pharmaceuticals, Inc.は、中国における伝統的な漢方薬（TCMP）の研究、開発、製造、マーケティング、販売を行っている。 詳細SXTC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ US市場と比較した過去 3 か月間の株価の変動意味のある収益がありません ( $2M )意味のある時価総額がありません ( $10M )すべてのリスクチェックを見るSXTC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.641.2k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-14m7m2016201920222025202620282031Revenue US$370.1kEarnings US$54.1kAdvancedSet Fair ValueView all narrativesChina SXT Pharmaceuticals, Inc. 競合他社cbdMDSymbol: NYSEAM:YCBDMarket cap: US$7.9mCannabist Company HoldingsSymbol: OTCPK:CBST.QMarket cap: US$15.8mNuminus WellnessSymbol: OTCPK:NUMI.FMarket cap: US$11.3mAkandaSymbol: NasdaqCM:AKANMarket cap: US$7.8m価格と性能株価の高値、安値、推移の概要China SXT Pharmaceuticals過去の株価現在の株価US$1.6452週高値US$1,046.9852週安値US$1.25ベータ1.961ヶ月の変化-19.61%3ヶ月変化-30.95%1年変化-99.32%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Apr 09China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $0.38 Transaction Features: Registered Direct Offeringお知らせ • Jan 14China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million.China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $0.15 Discount Per Security: $0.0105 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 54,666,666 Price\Range: $0.149 Discount Per Security: $0.01043 Transaction Features: Registered Direct OfferingNew Risk • Jan 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$17.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.5m revenue). Market cap is less than US$100m (US$17.5m market cap).お知らせ • Jan 10China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 66,666,666 Price\Range: $0.15 Transaction Features: Registered Direct OfferingNew Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risk Revenue is less than US$5m (US$1.5m revenue).Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).最新情報をもっと見るRecent updatesお知らせ • Apr 09China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $0.38 Transaction Features: Registered Direct Offeringお知らせ • Jan 14China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million.China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $0.15 Discount Per Security: $0.0105 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 54,666,666 Price\Range: $0.149 Discount Per Security: $0.01043 Transaction Features: Registered Direct OfferingNew Risk • Jan 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$17.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.5m revenue). Market cap is less than US$100m (US$17.5m market cap).お知らせ • Jan 10China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 66,666,666 Price\Range: $0.15 Transaction Features: Registered Direct OfferingNew Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risk Revenue is less than US$5m (US$1.5m revenue).Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).Reported Earnings • Aug 01Full year 2025 earnings released: US$2.32 loss per share (vs US$28.58 loss in FY 2024)Full year 2025 results: US$2.32 loss per share. Revenue: US$1.74m (down 9.7% from FY 2024). Net loss: US$3.30m (loss widened 6.6% from FY 2024).Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$1.55, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.Valuation Update With 7 Day Price Move • May 07Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.お知らせ • May 07China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 200,000 Price\Range: $0.5 Transaction Features: Registered Direct OfferingValuation Update With 7 Day Price Move • Apr 15Investor sentiment deteriorates as stock falls 32%After last week's 32% share price decline to US$1.70, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.Reported Earnings • Apr 03First half 2025 earnings released: US$1.99 loss per share (vs US$155 loss in 1H 2024)First half 2025 results: US$1.99 loss per share (improved from US$155 loss in 1H 2024). Net loss: US$802.6k (loss narrowed 92% from 1H 2024).New Risk • Apr 02New major risk - Revenue and earnings growthRevenue has declined by 2.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue has declined by 2.2% over the past year. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.12m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).お知らせ • Mar 18China SXT Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that the Company received a written notification (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Minimum Bid Price Requirement. Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company was provided with 180 calendar days, or until April 1, 2025, to regain compliance. To comply with the Minimum Bid Price Requirement, the closing bid price of the Company’s ordinary shares must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to April 1, 2025. Therefore, in order to cure the Minimum Bid Price deficiency, the Company has effectuated a share consolidation on February 25, 2025, of which every eight (8) issued and unissued ordinary shares of the Company with no par value each be consolidated into one (1) share with no par value. According to the Compliance Notice, the Company evidenced a closing bid price of its ordinary shares at or greater than $1.00 per share for 10 consecutive business days from February 25, 2025 to March 12, 2025. Thus, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is closed.New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.96m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.19m market cap). Minor Risk Revenue is less than US$5m (US$1.9m revenue).お知らせ • Feb 22China SXT Pharmaceuticals, Inc. Announces Share Consolidation to Regain Compliance with the Minimum Bid Price RequirementChina SXT Pharmaceutics, Inc. announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 25, 2025. Upon the market opening on February 25, 2025, the Company’s ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P157. The Company’s Board of Directors approved the afore-mentioned Share Consolidation so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market (the “Minimum Bid Price Requirement”). In order to maintain the Company’s listing on the Nasdaq Stock Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by April 1, 2025. There can be no assurance that following the Share Consolidation, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period to regain listing compliance. In the event that the Company does not regain compliance with the Minimum Bid Price Requirement, its securities may be subject to delisting from the Nasdaq Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.お知らせ • Jan 25China SXT Pharmaceuticals, Inc. Announces CEO ChangesOn January 20, 2025, the Board of China SXT Pharmaceuticals, Inc. approved the appointment of Mr. Simon Lim Sze Beng as the Co-Chief Executive Officer (the "Co-CEO") of the Company with immediate effect. In connection with this appointment, the title of Mr. Feng Zhou was changed from the Chief Executive Officer and Director to the Co-CEO and Director of the Company. Mr. Simon Lim Sze Beng is an experienced professional in the healthcare sector. Since 2019, he has served as a manager of Reform Medical Marketing Co., Limited, where he serves clients in medical, and healthcare sectors and promotes their products and services. From 2017 to 2019, he was the senior operations director at Axcel Digital, where he conducts multichannel promotion for healthcare sector clients. He earned a bachelor's degree in arts from Universiti Malaya in Malaysia in 2001.お知らせ • Jan 24China SXT Pharmaceuticals, Inc. Announces Board and Committee ChangesOn January 20, 2025, Songfan He resigned from his positions as an independent director of the board of directors of China SXT Pharmaceuticals, Inc., the chairman of the audit committee, a member of the compensation committee and nominating & corporate governance committee, effective immediately. Mr. He indicated that his resignation was due to personal reasons and was not the result of any disagreement with management of the Company or the Board. On January 20, 2025, the Board of the Company passed a resolution to appoint Mr. Yong Lip Chee as an independent director of the Board, the chairman of the Audit Committee, a member of the Compensation Committee and the Nominating Committee, to fill in the vacancies result from Mr. He's resignation. Mr. Yong Lip Chee has a background in sales and client relations within the healthcare sector. Since 2021, Mr. Yong has been an independent sales consultant, advising healthcare companies on market penetration strategies and distributor partnerships. From 2017 to 2021, he served as a sales supervisor at Winner Medical Hong Kong, where he promotes medical consumables products to hospitals and private healthcare medical professionals and related users. He earned a bachelor's degree in business administration from Universiti Malaya in Malaysia in 2013.お知らせ • Oct 08China SXT Pharmaceuticals Receives Nasdaq Notification Letter Regarding Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s ordinary shares on Nasdaq. Under the Nasdaq Listing Rules, the Company has until April 1, 2025, to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s ordinary shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance. If the Company does not regain compliance during such 180-day period, the Company may be eligible for an additional 180 calendar days, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq except for Nasdaq Listing Rule 5550(a)(2), and provide a written notice of its intention to cure this deficiency during the second compliance period, by effecting a reverse stock split, if necessary.お知らせ • Aug 01China SXT Pharmaceuticals, Inc. announced delayed 20-F filingOn 07/31/2024, China SXT Pharmaceuticals, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.New Risk • Apr 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 74% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Market cap is less than US$10m (US$1.08m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$1.7m revenue).New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Market cap is less than US$10m (US$1.23m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (US$2.0m revenue).お知らせ • Oct 27China SXT Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price RuleChina SXT Pharmaceuticals, Inc. announced that on October 19, 2023, NASDAQ notified us that it has determined that for the 10 consecutive business days, from October 5, 2023 to October 13, 2023, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter.お知らせ • Oct 05China SXT Pharmaceuticals Announces One-for-Twenty-Five Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Stock MarketChina SXT Pharmaceuticals, Inc. (the ‘company’) announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares. The Company’s ordinary shares will begin trading on the NASDAQ Stock Market on a split-adjusted basis when the market opens on October 5, 2023. The CUSIP number for the Company’s ordinary shares will be changed to G2161P140. The Company’s Board of Directors approved a reverse stock split so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Stock Market. In order to maintain the Company’s listing on the NASDAQ Capital Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by October 30, 2023. There can be no assurance that following the reverse split, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period as of October 30, 2023 to regain listing compliance. In the event the Company does not regain compliance with the minimum bid price requirement, its securities may be subject to delisting from the NASDAQ Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.Reported Earnings • Aug 01Full year 2023 earnings released: US$0.89 loss per share (vs US$5.52 loss in FY 2022)Full year 2023 results: US$0.89 loss per share. Net loss: US$5.93m (loss widened 3.5% from FY 2022).お知らせ • May 11China SXT Pharmaceuticals Receives 180-Day Extension from Nasdaq to Meet Minimum Bid Price RuleOn May 10, 2023, China SXT Pharmaceuticals, Inc. announced that on May 4, 2023, the company received a written notification from the Nasdaq's Listing Qualifications Department, granting the company another 180 calendar days extension, or until October 30, 2023, to regain compliance with Nasdaq’s minimum bid price requirement. The company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period. The Company intends to regain compliance with the minimum bid price requirement on or before October 30, 2023 and is considering all available options, including a reverse stock split if necessary. During this time, the Company's ordinary shares will continue to be listed and traded on the Nasdaq Capital Market, and this notice will have no effect on the operations of the Company’s business.Reported Earnings • Feb 26First half 2023 earnings released: US$0.58 loss per share (vs US$3.98 loss in 1H 2022)First half 2023 results: US$0.58 loss per share (improved from US$3.98 loss in 1H 2022). Revenue: US$1.21m (up 18% from 1H 2022). Net loss: US$1.49m (loss narrowed 52% from 1H 2022).Reported Earnings • Jul 19Full year 2022 earnings released: US$5.52 loss per share (vs US$3.82 loss in FY 2021)Full year 2022 results: US$5.52 loss per share (down from US$3.82 loss in FY 2021). Revenue: US$2.60m (down 46% from FY 2021). Net loss: US$5.74m (loss widened 109% from FY 2021).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jan 19First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: US$0.20 loss per share (down from US$0.096 profit in 1H 2021). Revenue: US$1.03m (down 73% from 1H 2021). Net loss: US$3.09m (down 324% from profit in 1H 2021). Revenue was in line with analyst estimates.Board Change • Nov 02Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Junsong Li is the most experienced director on the board, commencing their role in 2019. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Is New 90 Day High Low • Feb 17New 90-day high: US$1.28The company is up 360% from its price of US$0.28 on 18 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 15% over the same period.分析記事 • Feb 09China SXT Pharmaceuticals'(NASDAQ:SXTC) Share Price Is Down 12% Over The Past Year.It is doubtless a positive to see that the China SXT Pharmaceuticals, Inc. ( NASDAQ:SXTC ) share price has gained some...Reported Earnings • Jan 31First half 2021 earnings released: EPS US$0.026 (vs US$0.10 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$3.86m (up 20% from 1H 2020). Net income: US$1.38m (up US$3.73m from 1H 2020). Profit margin: 36% (up from net loss in 1H 2020).Is New 90 Day High Low • Jan 30New 90-day high: US$0.73The company is up 157% from its price of US$0.28 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 17% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: US$0.39The company is up 56% from its price of US$0.25 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period.Is New 90 Day High Low • Dec 02New 90-day high: US$0.34The company is up 28% from its price of US$0.27 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 14% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: US$0.23The company is down 52% from its price of US$0.48 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 8.0% over the same period.株主還元SXTCUS PharmaceuticalsUS 市場7D2.5%-0.1%-0.3%1Y-99.3%38.7%26.7%株主還元を見る業界別リターン: SXTC過去 1 年間で38.7 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: SXTCは、過去 1 年間で26.7 % のリターンを上げたUS市場を下回りました。価格変動Is SXTC's price volatile compared to industry and market?SXTC volatilitySXTC Average Weekly Movement14.4%Pharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: SXTCの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: SXTCの 週次ボラティリティ は過去 1 年間で24%から14%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200575Albert Zhouwww.sxtchina.com製薬会社である中国SXT医薬有限公司は、中国における中医薬品（TCMP）の研究、開発、製造、マーケティング、販売を行っている。同社は、高度な、微細な、通常のTCMP製品、およびSanQiFen、HongQi、SuMu、JiangXiang、CuYanHuSuoなどの生薬を提供しています、夏天武、呂雪京、雪碣、曹源蔵仁、洪克己、川北木、黄秀桂花、五維子、丁香、仁神、清国、冉明子、沙仁、陳香などの生薬がある。Suxuantang、Hui Chun Tang、Tong Ren Tangのブランドで製品を提供している。同社は製薬会社、チェーン薬局、病院、医薬品販売業者にサービスを提供している。China SXT Pharmaceuticals, Inc.は2005年に設立され、中国の台州に本社を置いている。もっと見るChina SXT Pharmaceuticals, Inc. 基礎のまとめChina SXT Pharmaceuticals の収益と売上を時価総額と比較するとどうか。SXTC 基礎統計学時価総額US$10.33m収益（TTM）-US$8.87m売上高(TTM)US$1.54m6.9xP/Sレシオ-1.2xPER（株価収益率SXTC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SXTC 損益計算書（TTM）収益US$1.54m売上原価US$1.20m売上総利益US$334.40kその他の費用US$9.20m収益-US$8.87m直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）-1.37グロス・マージン21.74%純利益率-576.72%有利子負債／自己資本比率5.2%SXTC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 22:03終値2026/05/21 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋China SXT Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 09China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $0.38 Transaction Features: Registered Direct Offering
お知らせ • Jan 14China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million.China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $0.15 Discount Per Security: $0.0105 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 54,666,666 Price\Range: $0.149 Discount Per Security: $0.01043 Transaction Features: Registered Direct Offering
New Risk • Jan 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$17.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.5m revenue). Market cap is less than US$100m (US$17.5m market cap).
お知らせ • Jan 10China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 66,666,666 Price\Range: $0.15 Transaction Features: Registered Direct Offering
New Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risk Revenue is less than US$5m (US$1.5m revenue).
Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).
お知らせ • Apr 09China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $0.38 Transaction Features: Registered Direct Offering
お知らせ • Jan 14China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million.China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $0.15 Discount Per Security: $0.0105 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 54,666,666 Price\Range: $0.149 Discount Per Security: $0.01043 Transaction Features: Registered Direct Offering
New Risk • Jan 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$17.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.5m revenue). Market cap is less than US$100m (US$17.5m market cap).
お知らせ • Jan 10China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 66,666,666 Price\Range: $0.15 Transaction Features: Registered Direct Offering
New Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risk Revenue is less than US$5m (US$1.5m revenue).
Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).
Reported Earnings • Aug 01Full year 2025 earnings released: US$2.32 loss per share (vs US$28.58 loss in FY 2024)Full year 2025 results: US$2.32 loss per share. Revenue: US$1.74m (down 9.7% from FY 2024). Net loss: US$3.30m (loss widened 6.6% from FY 2024).
Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$1.55, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.
Valuation Update With 7 Day Price Move • May 07Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.
お知らせ • May 07China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 200,000 Price\Range: $0.5 Transaction Features: Registered Direct Offering
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment deteriorates as stock falls 32%After last week's 32% share price decline to US$1.70, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.
Reported Earnings • Apr 03First half 2025 earnings released: US$1.99 loss per share (vs US$155 loss in 1H 2024)First half 2025 results: US$1.99 loss per share (improved from US$155 loss in 1H 2024). Net loss: US$802.6k (loss narrowed 92% from 1H 2024).
New Risk • Apr 02New major risk - Revenue and earnings growthRevenue has declined by 2.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue has declined by 2.2% over the past year. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.12m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).
お知らせ • Mar 18China SXT Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that the Company received a written notification (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Minimum Bid Price Requirement. Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company was provided with 180 calendar days, or until April 1, 2025, to regain compliance. To comply with the Minimum Bid Price Requirement, the closing bid price of the Company’s ordinary shares must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to April 1, 2025. Therefore, in order to cure the Minimum Bid Price deficiency, the Company has effectuated a share consolidation on February 25, 2025, of which every eight (8) issued and unissued ordinary shares of the Company with no par value each be consolidated into one (1) share with no par value. According to the Compliance Notice, the Company evidenced a closing bid price of its ordinary shares at or greater than $1.00 per share for 10 consecutive business days from February 25, 2025 to March 12, 2025. Thus, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is closed.
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.96m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.19m market cap). Minor Risk Revenue is less than US$5m (US$1.9m revenue).
お知らせ • Feb 22China SXT Pharmaceuticals, Inc. Announces Share Consolidation to Regain Compliance with the Minimum Bid Price RequirementChina SXT Pharmaceutics, Inc. announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 25, 2025. Upon the market opening on February 25, 2025, the Company’s ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P157. The Company’s Board of Directors approved the afore-mentioned Share Consolidation so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market (the “Minimum Bid Price Requirement”). In order to maintain the Company’s listing on the Nasdaq Stock Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by April 1, 2025. There can be no assurance that following the Share Consolidation, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period to regain listing compliance. In the event that the Company does not regain compliance with the Minimum Bid Price Requirement, its securities may be subject to delisting from the Nasdaq Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.
お知らせ • Jan 25China SXT Pharmaceuticals, Inc. Announces CEO ChangesOn January 20, 2025, the Board of China SXT Pharmaceuticals, Inc. approved the appointment of Mr. Simon Lim Sze Beng as the Co-Chief Executive Officer (the "Co-CEO") of the Company with immediate effect. In connection with this appointment, the title of Mr. Feng Zhou was changed from the Chief Executive Officer and Director to the Co-CEO and Director of the Company. Mr. Simon Lim Sze Beng is an experienced professional in the healthcare sector. Since 2019, he has served as a manager of Reform Medical Marketing Co., Limited, where he serves clients in medical, and healthcare sectors and promotes their products and services. From 2017 to 2019, he was the senior operations director at Axcel Digital, where he conducts multichannel promotion for healthcare sector clients. He earned a bachelor's degree in arts from Universiti Malaya in Malaysia in 2001.
お知らせ • Jan 24China SXT Pharmaceuticals, Inc. Announces Board and Committee ChangesOn January 20, 2025, Songfan He resigned from his positions as an independent director of the board of directors of China SXT Pharmaceuticals, Inc., the chairman of the audit committee, a member of the compensation committee and nominating & corporate governance committee, effective immediately. Mr. He indicated that his resignation was due to personal reasons and was not the result of any disagreement with management of the Company or the Board. On January 20, 2025, the Board of the Company passed a resolution to appoint Mr. Yong Lip Chee as an independent director of the Board, the chairman of the Audit Committee, a member of the Compensation Committee and the Nominating Committee, to fill in the vacancies result from Mr. He's resignation. Mr. Yong Lip Chee has a background in sales and client relations within the healthcare sector. Since 2021, Mr. Yong has been an independent sales consultant, advising healthcare companies on market penetration strategies and distributor partnerships. From 2017 to 2021, he served as a sales supervisor at Winner Medical Hong Kong, where he promotes medical consumables products to hospitals and private healthcare medical professionals and related users. He earned a bachelor's degree in business administration from Universiti Malaya in Malaysia in 2013.
お知らせ • Oct 08China SXT Pharmaceuticals Receives Nasdaq Notification Letter Regarding Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s ordinary shares on Nasdaq. Under the Nasdaq Listing Rules, the Company has until April 1, 2025, to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s ordinary shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance. If the Company does not regain compliance during such 180-day period, the Company may be eligible for an additional 180 calendar days, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq except for Nasdaq Listing Rule 5550(a)(2), and provide a written notice of its intention to cure this deficiency during the second compliance period, by effecting a reverse stock split, if necessary.
お知らせ • Aug 01China SXT Pharmaceuticals, Inc. announced delayed 20-F filingOn 07/31/2024, China SXT Pharmaceuticals, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
New Risk • Apr 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 74% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Market cap is less than US$10m (US$1.08m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$1.7m revenue).
New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Market cap is less than US$10m (US$1.23m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (US$2.0m revenue).
お知らせ • Oct 27China SXT Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price RuleChina SXT Pharmaceuticals, Inc. announced that on October 19, 2023, NASDAQ notified us that it has determined that for the 10 consecutive business days, from October 5, 2023 to October 13, 2023, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter.
お知らせ • Oct 05China SXT Pharmaceuticals Announces One-for-Twenty-Five Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Stock MarketChina SXT Pharmaceuticals, Inc. (the ‘company’) announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares. The Company’s ordinary shares will begin trading on the NASDAQ Stock Market on a split-adjusted basis when the market opens on October 5, 2023. The CUSIP number for the Company’s ordinary shares will be changed to G2161P140. The Company’s Board of Directors approved a reverse stock split so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Stock Market. In order to maintain the Company’s listing on the NASDAQ Capital Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by October 30, 2023. There can be no assurance that following the reverse split, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period as of October 30, 2023 to regain listing compliance. In the event the Company does not regain compliance with the minimum bid price requirement, its securities may be subject to delisting from the NASDAQ Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.
Reported Earnings • Aug 01Full year 2023 earnings released: US$0.89 loss per share (vs US$5.52 loss in FY 2022)Full year 2023 results: US$0.89 loss per share. Net loss: US$5.93m (loss widened 3.5% from FY 2022).
お知らせ • May 11China SXT Pharmaceuticals Receives 180-Day Extension from Nasdaq to Meet Minimum Bid Price RuleOn May 10, 2023, China SXT Pharmaceuticals, Inc. announced that on May 4, 2023, the company received a written notification from the Nasdaq's Listing Qualifications Department, granting the company another 180 calendar days extension, or until October 30, 2023, to regain compliance with Nasdaq’s minimum bid price requirement. The company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period. The Company intends to regain compliance with the minimum bid price requirement on or before October 30, 2023 and is considering all available options, including a reverse stock split if necessary. During this time, the Company's ordinary shares will continue to be listed and traded on the Nasdaq Capital Market, and this notice will have no effect on the operations of the Company’s business.
Reported Earnings • Feb 26First half 2023 earnings released: US$0.58 loss per share (vs US$3.98 loss in 1H 2022)First half 2023 results: US$0.58 loss per share (improved from US$3.98 loss in 1H 2022). Revenue: US$1.21m (up 18% from 1H 2022). Net loss: US$1.49m (loss narrowed 52% from 1H 2022).
Reported Earnings • Jul 19Full year 2022 earnings released: US$5.52 loss per share (vs US$3.82 loss in FY 2021)Full year 2022 results: US$5.52 loss per share (down from US$3.82 loss in FY 2021). Revenue: US$2.60m (down 46% from FY 2021). Net loss: US$5.74m (loss widened 109% from FY 2021).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jan 19First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: US$0.20 loss per share (down from US$0.096 profit in 1H 2021). Revenue: US$1.03m (down 73% from 1H 2021). Net loss: US$3.09m (down 324% from profit in 1H 2021). Revenue was in line with analyst estimates.
Board Change • Nov 02Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Junsong Li is the most experienced director on the board, commencing their role in 2019. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Is New 90 Day High Low • Feb 17New 90-day high: US$1.28The company is up 360% from its price of US$0.28 on 18 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 15% over the same period.
分析記事 • Feb 09China SXT Pharmaceuticals'(NASDAQ:SXTC) Share Price Is Down 12% Over The Past Year.It is doubtless a positive to see that the China SXT Pharmaceuticals, Inc. ( NASDAQ:SXTC ) share price has gained some...
Reported Earnings • Jan 31First half 2021 earnings released: EPS US$0.026 (vs US$0.10 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$3.86m (up 20% from 1H 2020). Net income: US$1.38m (up US$3.73m from 1H 2020). Profit margin: 36% (up from net loss in 1H 2020).
Is New 90 Day High Low • Jan 30New 90-day high: US$0.73The company is up 157% from its price of US$0.28 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 17% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: US$0.39The company is up 56% from its price of US$0.25 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period.
Is New 90 Day High Low • Dec 02New 90-day high: US$0.34The company is up 28% from its price of US$0.27 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 14% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: US$0.23The company is down 52% from its price of US$0.48 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 8.0% over the same period.
